studies

renal cell cancer (RCC), everolimus vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 025, 2015 (REV) 1.37 [1.07; 1.75] KEYNOTE-581/CLEAR (mtor), 2021 1.15 [0.88; 1.50] 1.26[1.06; 1.51]CheckMate 025, 2015 (REV), KEYNOTE-581/CLEAR (mtor), 202120%1,535moderatenot evaluable progression or deaths (PFS)detailed resultsCheckMate 025, 2015 (REV) 1.14 [0.97; 1.33] KEYNOTE-581/CLEAR (mtor), 2021 0.65 [0.53; 0.80] 0.86[0.50; 1.49]CheckMate 025, 2015 (REV), KEYNOTE-581/CLEAR (mtor), 2021294%1,535moderatenot evaluable objective responses (ORR)detailed resultsCheckMate 025, 2015 (REV) 0.17 [0.10; 0.27] KEYNOTE-581/CLEAR (mtor), 2021 1.48 [1.26; 1.74] 0.50[0.06; 4.27]CheckMate 025, 2015 (REV), KEYNOTE-581/CLEAR (mtor), 2021299%1,535moderatenot evaluable AE (any grade)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 5.28 [0.61; 45.46] 5.28[0.61; 45.46]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 1.53 [1.09; 2.14] 1.53[1.09; 2.14]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 1.98 [0.94; 4.14] 1.98[0.94; 4.14]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 2.20 [1.50; 3.23] 2.20[1.50; 3.23]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable TRAE (any grade)detailed resultsCheckMate 025, 2015 (REV) 1.98 [1.35; 2.91] 1.98[1.35; 2.91]CheckMate 025, 2015 (REV)10%803NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 2.50 [1.81; 3.45] 2.50[1.81; 3.45]CheckMate 025, 2015 (REV)10%803NAnot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 025, 2015 (REV) 4.11 [0.18; 91.35] 4.11[0.18; 91.35]CheckMate 025, 2015 (REV)10%803NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 025, 2015 (REV) 1.82 [1.14; 2.91] 1.82[1.14; 2.91]CheckMate 025, 2015 (REV)10%803NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 4.83 [2.10; 11.10] 4.83[2.10; 11.10]CheckMate 025, 2015 (REV)10%803NAnot evaluable Cough TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 2.06 [0.37; 11.29] 2.06[0.37; 11.29]CheckMate 025, 2015 (REV)10%803NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.29; 3.56] 1.02[0.29; 3.56]CheckMate 025, 2015 (REV)10%803NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 0.68 [0.11; 4.09] 0.68[0.11; 4.09]CheckMate 025, 2015 (REV)10%803NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.13 [0.47; 2.69] 1.13[0.47; 2.69]CheckMate 025, 2015 (REV)10%803NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsOut of scaleCheckMate 025, 2015 (REV) 25.28 [1.49; 429.40] 25.28[1.49; 429.40]CheckMate 025, 2015 (REV)10%803NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 3.08 [0.32; 29.77] 3.08[0.32; 29.77]CheckMate 025, 2015 (REV)10%803NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 4.11 [0.18; 91.35] 4.11[0.18; 91.35]CheckMate 025, 2015 (REV)10%803NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.90 [0.70; 5.19] 1.90[0.70; 5.19]CheckMate 025, 2015 (REV)10%803NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.54 [0.26; 9.25] 1.54[0.26; 9.25]CheckMate 025, 2015 (REV)10%803NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsOut of scaleCheckMate 025, 2015 (REV) 36.28 [2.17; 606.14] 36.28[2.17; 606.14]CheckMate 025, 2015 (REV)10%803NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 4.84 [0.56; 41.67] 4.84[0.56; 41.67]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 1.92 [0.06; 57.36] 1.92[0.06; 57.36]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 4.43 [1.66; 11.83] 4.43[1.66; 11.83]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 2.34 [1.31; 4.15] 2.34[1.31; 4.15]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 0.48 [0.02; 14.30] 0.48[0.02; 14.30]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Dysphonia AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 3.85 [0.17; 85.62] 3.85[0.17; 85.62]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 1.78 [0.93; 3.41] 1.78[0.93; 3.41]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Hypertension AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 1.25 [0.87; 1.81] 1.25[0.87; 1.81]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 3.85 [0.17; 85.62] 3.85[0.17; 85.62]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 4.40 [0.94; 20.50] 4.40[0.94; 20.50]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 0.73 [0.32; 1.69] 0.73[0.32; 1.69]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Proteinuria AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 2.94 [1.41; 6.12] 2.94[1.41; 6.12]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 0.48 [0.04; 5.29] 0.48[0.04; 5.29]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 3.14 [1.32; 7.46] 3.14[1.32; 7.46]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-581/CLEAR (mtor), 2021 1.94 [0.66; 5.74] 1.94[0.66; 5.74]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsOut of scaleKEYNOTE-581/CLEAR (mtor), 2021 26.79 [3.61; 198.57] 26.79[3.61; 198.57]KEYNOTE-581/CLEAR (mtor), 202110%695NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-05-20 20:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 10,93,79,178,152,80 - treatments: 507,1040

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons